Merck buys rights to heart disease drug in latest China deal
Merck has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, ...
Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up
AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.
BioPharma Dive9d
Merck bets $200M on a new type of heart pill
A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...
Merck & Co.: Looming Patent Expiries For Key Drugs Weaken Longer-Term Outlook
Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.
Merck plans to launch US subcutaneous version of Keytruda on October 1
Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...
Fierce Biotech3d
Merck KGaA pays $85M to nab global rights for Abbisko's rare tumor drug after phase 3 win
With the CSF-1R inhibitor space heating up, Merck KGaA has gone all-in on pimicotinib, paying Abbisko Therapeutics $85 ...
BioSpace3d
Merck’s Winrevair Cuts Morbidity, Mortality Risk by Over 75% in Phase III PAH Study
In high-risk patients with pulmonary arterial hypertension, Merck ’s fusion protein therapeutic Winrevair reduced the ...
Seeking Alpha9d
Merck & Co.: Looming Patent Expiries For Key Drugs Weaken Longer-Term Outlook
Despite attractive valuation metrics, the uncertainty surrounding Merck's future drug portfolio and revenue generation makes it a less favorable buy at this time. MRK stock's annual dividend yield ...